In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Pharmaceutical
Context Therapeutics, a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and the Menarini Group have announced a clinical trial collaboration and supply agreement for the latter firm’s oral selective estrogen receptor degrader, elacestrant. 2 August 2022
Biotechnology
Oncology-focused Australian drug development company Kazia Therapeutics lost more than 50% of its stock market value on Monday. 2 August 2022
Pharmaceutical
Shares of Sosei Group were up nearly 5% at 1,500 yen today, as it announced a lucrative deal with US pharma major AbbVie. 2 August 2022
Biotechnology
Pre-clinical stage gene therapy company AviadoBio has announced the appointment of David Cooper as chief medical officer (CMO). 2 August 2022
Biotechnology
USA-based clinical-state biopharma firm IDRx, which is dedicated to transforming cancer treatment with purpose-built precision combination therapies, launched today with a $122 million oversubscribed Series A financing. 2 August 2022
Pharmaceutical
A new analysis by the health care analytics and research firm Avalere reveals the US Senate’s partisan drug pricing bill will have a much deeper impact on the biopharmaceutical research industry than previously reported, noted the leading US sector lobby group Pharmaceutical Research and Manufacturers of America (PhRMA), which gave its assessment of the implications. 2 August 2022
Pharmaceutical
German biopharma Vivoryon Therapeutics has announced results for its Alzheimer’s disease (AD) drug candidate varoglutamstat from the ongoing European Phase IIb study VIVIAD. 2 August 2022
Biotechnology
USA-based GreenLight Biosciences, a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible, saw its shares close up almost 10% at $2.33 yesterday, after it announced the successful completion of the first commercial-scale engineering run for the mRNA production partnership with South Korean contract development and manufacturing organization (CDMO), Samsung Biologics. 2 August 2022
Biotechnology
GluBio Therapeutics, a Sino-American biotech developing novel targeted protein degradation (TPD) drugs, has completed a Series A+ financing of $22 million. 2 August 2022
Pharmaceutical
Scientists at the Russian Granov Scientific Center for Radiology and Surgical Technologies have developed a new drug, which could be recommended for the use against severe forms of cancer, reports The Pharma Letter’s local correspondent. 2 August 2022
Biotechnology
OriCell Therapeutics has announced the completion of Series B financing totaling more than $120 million, which was jointly led by Qiming Venture Partners and Quan Capital. 2 August 2022
Biotechnology
Belgian clinical-stage biotech Celyad Oncology, which is focused on the discovery and development of chimeric antigen receptor T cell (CAR-T) therapies for cancer, yesterday announced that the US Food and Drug Administration (FDA) has lifted the clinical hold on the CYAD-101-002 (KEYNOTE-B79) Phase Ib trial after the company made changes to the eligibility criteria for the trial. 2 August 2022
Biotechnology
Swiss pharma giant Roche today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of its cancer immunotherapy Tecentriq (atezolizumab) met its co-primary endpoints. 2 August 2022
Biotechnology
US healthcare giant Johnson & Johnson’s Janssen subsidiary today announced that the US Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). 1 August 2022
Generics
Shares in Sun Pharma closed more than 5% higher on Friday. 1 August 2022
Pharmaceutical
Thousands more people in the UK will get potentially life-saving treatment for hepatitis C thanks to a new National Health Service (NHS) screening pilot – driving forward the NHS ambition to eliminate the virus by 2030. 1 August 2022
Pharmaceutical
UK-based Arecor Therapeutics has announced that it is to acquire Tetris Pharma. 1 August 2022
Biotechnology
German independent research institute BioMed X has announced the start of its new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with the healthcare business of Germany’s Merck KGaA. 1 August 2022
Pharmaceutical
German glass company Schott has established a stand-alone company for its pharma business to advance its growth strategy. 1 August 2022
Biotechnology
French drugmaker Ipsen and USA-based immuno-oncology start-up Marengo Therapeutics today announced a strategic partnership to advance two of Marengo’s pre-clinical STAR platform-generated candidates into the clinic. 1 August 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze